MA49727B1 - Anticorps et polypeptides dirigés contre cd127 - Google Patents

Anticorps et polypeptides dirigés contre cd127

Info

Publication number
MA49727B1
MA49727B1 MA49727A MA49727A MA49727B1 MA 49727 B1 MA49727 B1 MA 49727B1 MA 49727 A MA49727 A MA 49727A MA 49727 A MA49727 A MA 49727A MA 49727 B1 MA49727 B1 MA 49727B1
Authority
MA
Morocco
Prior art keywords
antibodies
directed against
polypeptides directed
diagnostic applications
therapeutic
Prior art date
Application number
MA49727A
Other languages
English (en)
Other versions
MA49727A (fr
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Virginie Thepenier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA49727A publication Critical patent/MA49727A/fr
Publication of MA49727B1 publication Critical patent/MA49727B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

L'invention concerne le domaine des anticorps utiles dans des applications thérapeutiques et de diagnostic ciblant le cd127, la chaîne alpha du récepteur il7, et fournit en particulier des anticorps monoclonaux humanisés contre le cd127, en particulier le cd127 humain, leurs utilisations thérapeutiques et des applications de diagnostic.
MA49727A 2016-12-09 2017-12-07 Anticorps et polypeptides dirigés contre cd127 MA49727B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306655 2016-12-09
PCT/EP2017/081911 WO2018104483A1 (fr) 2016-12-09 2017-12-07 Anticorps et polypeptides dirigés contre cd127

Publications (2)

Publication Number Publication Date
MA49727A MA49727A (fr) 2019-10-16
MA49727B1 true MA49727B1 (fr) 2021-05-31

Family

ID=57796143

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49727A MA49727B1 (fr) 2016-12-09 2017-12-07 Anticorps et polypeptides dirigés contre cd127

Country Status (37)

Country Link
US (2) US11098128B2 (fr)
EP (1) EP3551664B1 (fr)
JP (1) JP6986559B2 (fr)
KR (1) KR102306366B1 (fr)
CN (1) CN110392695B (fr)
AR (1) AR110326A1 (fr)
AU (1) AU2017373819B2 (fr)
BR (1) BR112019010595A2 (fr)
CA (1) CA3042582C (fr)
CL (1) CL2019001530A1 (fr)
CO (1) CO2019005909A2 (fr)
CR (1) CR20190273A (fr)
CY (1) CY1124153T1 (fr)
DK (1) DK3551664T3 (fr)
EA (1) EA201991005A1 (fr)
ES (1) ES2867900T3 (fr)
HR (1) HRP20210697T1 (fr)
HU (1) HUE054206T2 (fr)
IL (1) IL266837B (fr)
LT (1) LT3551664T (fr)
MA (1) MA49727B1 (fr)
MD (1) MD3551664T2 (fr)
MX (1) MX2019006577A (fr)
MY (1) MY190770A (fr)
NZ (1) NZ753213A (fr)
PE (1) PE20191152A1 (fr)
PH (1) PH12019501285A1 (fr)
PL (1) PL3551664T3 (fr)
PT (1) PT3551664T (fr)
RS (1) RS61808B1 (fr)
RU (1) RU2769352C2 (fr)
SA (1) SA519401906B1 (fr)
SI (1) SI3551664T1 (fr)
TW (1) TWI777996B (fr)
UA (1) UA126386C2 (fr)
UY (1) UY37511A (fr)
WO (1) WO2018104483A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154293A1 (fr) * 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Anticorps contre la sous-unité alpha d'un l'il-7r et leurs utilisations
EP3986931A1 (fr) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
CA3144567A1 (fr) * 2019-06-21 2020-12-24 Scott Crowe Polypeptides
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN113501499A (zh) * 2021-08-11 2021-10-15 无锡贝塔医药科技有限公司 一种高纯无水溴化氘气体的制备方法及其应用
WO2023232826A1 (fr) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarqueurs de l'activité du modulateur de l'il7r

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
AR080027A1 (es) * 2010-01-28 2012-03-07 Glaxo Group Ltd Proteinas de union a cd127
TWI596114B (zh) * 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
EP2583980A1 (fr) 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
MY190770A (en) 2022-05-12
DK3551664T3 (da) 2021-05-03
CR20190273A (es) 2019-10-17
PH12019501285A1 (en) 2019-12-16
EA201991005A1 (ru) 2019-12-30
RU2019115610A (ru) 2021-01-12
HRP20210697T1 (hr) 2021-07-23
CA3042582A1 (fr) 2018-06-14
JP2020500542A (ja) 2020-01-16
PE20191152A1 (es) 2019-09-05
IL266837A (en) 2019-07-31
AU2017373819B2 (en) 2022-03-31
PL3551664T3 (pl) 2021-08-02
CN110392695B (zh) 2021-02-02
UA126386C2 (uk) 2022-09-28
US20190375844A1 (en) 2019-12-12
LT3551664T (lt) 2021-05-25
BR112019010595A2 (pt) 2019-09-17
UY37511A (es) 2018-06-29
KR102306366B1 (ko) 2021-09-29
HUE054206T2 (hu) 2021-08-30
TW201833137A (zh) 2018-09-16
CN110392695A (zh) 2019-10-29
US11098128B2 (en) 2021-08-24
AR110326A1 (es) 2019-03-20
AU2017373819A1 (en) 2019-05-30
CA3042582C (fr) 2023-05-23
JP6986559B2 (ja) 2022-01-05
SA519401906B1 (ar) 2022-12-20
EP3551664A1 (fr) 2019-10-16
KR20190090005A (ko) 2019-07-31
WO2018104483A1 (fr) 2018-06-14
US20210395376A1 (en) 2021-12-23
TWI777996B (zh) 2022-09-21
CY1124153T1 (el) 2022-05-27
US11926671B2 (en) 2024-03-12
CO2019005909A2 (es) 2019-07-31
CL2019001530A1 (es) 2019-10-11
RS61808B1 (sr) 2021-06-30
RU2769352C2 (ru) 2022-03-30
RU2019115610A3 (fr) 2021-04-05
EP3551664B1 (fr) 2021-02-17
MD3551664T2 (ro) 2021-06-30
ES2867900T3 (es) 2021-10-21
PT3551664T (pt) 2021-04-21
MX2019006577A (es) 2019-10-07
NZ753213A (en) 2022-05-27
IL266837B (en) 2020-06-30
MA49727A (fr) 2019-10-16
SI3551664T1 (sl) 2021-08-31
US20220332834A2 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12018501177A1 (en) Antibodies targeting fc receptor-like 5 and methods of use
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
MX2014013678A (es) Agentes para neutralizacion de influenza.
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
BR112018009004A2 (pt) conjugados anti-cd3-folato e seus usos
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана